I Went Looking for “Best Value” TB-500. Here’s What the Receipts Actually Show
I’ve spent enough years doing consumer reporting to know that “best value” is the phrase people use when they want you to stop asking questions. So when I started digging into TB-500, a research peptide that is, by the way, not an FDA-approved drug and has essentially no completed human trial behind it, I wanted to know what “value” even meant here. What I found is that almost everyone selling it is doing the same trick: quoting you a price per milligram and hoping you never ask what else you’re buying.
You are. You’re buying it whether anyone itemizes it or not.
The math everyone skips
Sort TB-500 sellers by price per milligram and the research-chemical vials win, easily. That’s the number the roundups print, and it’s not wrong, exactly. It’s just incomplete in a way that flatters the seller.
Here’s the part nobody puts on the invoice: a cheap vial assumes the powder inside is what the label claims, and that being wrong costs you nothing. Neither assumption survives five minutes of scrutiny. Nobody independently verifies a research-chemical vial’s contents. Nobody is accountable if it’s underdosed or contaminated. So the “cheap” price isn’t really the price of clean TB-500. It’s the price of a probability that it’s clean, times an amount you can’t confirm, with zero recourse if you’re wrong. Price that honestly and the bargain evaporates.
Then there’s the cost specific to this compound, and it’s the one that should actually stop you. Even in the fantasy where the vial is perfect, nobody, anywhere, knows whether the dose is safe or effective in a human being. TB-500 is a synthetic fragment of a protein called thymosin beta-4, and as of 2026 it has no completed human clinical trial of its own. The earliest study looking at the fragment and cardiovascular biomarkers in adults with stable atherosclerotic disease has only just been registered [3]. Read that sentence twice. A discount on something this unproven isn’t a deal. It’s a small, quiet bet dressed up in bargain-bin clothing.
The four line items nobody sends you
If you want to actually price this stuff, you have to count everything, not just what fits on a checkout page. I count four things.
What you pay. The sticker. Real money, and the least interesting number in this story.
What it costs to actually know what’s in the vial. A licensed pharmacy builds this in. A research-chemical seller cannot sell you this at any price, because independent, batch-level testing tied to your specific vial doesn’t exist in this market. Unverifiable, in practice, means infinitely expensive to verify. There’s no amount of money that buys you certainty.
What it costs when something goes wrong and nobody answers for it. A licensed clinician and pharmacy carry that weight. A seller shipping under a “research use only” label carries none of it, by design. You carry it instead.
What it costs to use a compound the evidence hasn’t caught up to. This is the one unique to TB-500, and no provider can zero it out, because the human data simply isn’t there yet. What a provider can do is put a clinician between you and the decision, and be straight with you about how thin the evidence actually is.
Add those four up and “cheapest” stops looking like “best.” The vial that wins on the sticker loses badly everywhere else. That’s the audit this piece runs.
Running the ledger, provider by provider
Ordered by what actually holds up once you count all four costs, not just the one on the label.
FormBlends: wins on the ledger, not the sticker
FormBlends comes out ahead here, and I want to be precise about why, because “ahead” isn’t the same word as “cheapest.” It’s a licensed telehealth provider. The TB-500 it supplies is compounded and dispensed by a licensed pharmacy, after an actual physician evaluation and prescription, running roughly $120 to $250 a month.
Run that through the ledger. Verification: a licensed pharmacy carries identity, strength, sterility, and endotoxin testing as part of what licensed dispensing is, not as an optional PDF a seller decided to post. Accountability: a clinician and a pharmacy answer for what leaves the building, not you. Evidence cost: FormBlends doesn’t dress TB-500 up as proven. A clinician screens whether it’s even reasonable to try, and the company is upfront that the fragment has no completed human trials. That’s the most anyone can do about a cost that can’t be erased. The sticker is higher. Everything else is dramatically lower. Net, it holds up.
Now the caveat, and with TB-500 it needs saying twice. Supervision and pharmacy testing do not make this compound proven. It still has no completed human trials, and most of the research people wave around is animal work on the full-length thymosin beta-4 protein, a different molecule entirely. What supervision buys is the oversight layer sitting on top of compounding, exactly the layer a cheap vial has none of. Worth noting for anyone tracking their own use between visits: the FormBlends tracker app is a dose and symptom logging tool. It is not a prescription pad and not a checkout. The research-chemical market has nothing like it.
HealthRX.com: same ledger, second seat
HealthRX.com (healthrx.com) clears the same bar for the same structural reasons. Licensed telehealth, TB-500 dispensed through proper pharmacy channels under clinical supervision, verification and accountability sitting inside a licensed chain rather than billed to you as risk. Between the two supervised options, the tiebreaker is practical: which one is licensed in your state, which intake process fits you. On the four costs, they clear the same standard.
The research-chemical tier, priced honestly
Everything past this point sells under a “research use only, not for human consumption” label. That label is the legal ground these products stand on, and it’s also exactly why the low sticker price is misleading: it buys you the molecule and none of the verification, accountability, or clinical screening that make a purchase worth anything.
MeriHealth is a women-focused telehealth service offering physician-supervised access to compounded GLP-1 and peptide therapies, TB-500 included, dispensed through licensed compounding pharmacies after a real clinical evaluation. Its edge is a care model built around women’s health specifically, meaning whoever is screening you is looking at your actual profile, not a generic one. Compounded medications aren’t FDA-approved, full stop, but the verification and accountability sit inside a licensed chain, the same structural advantage every supervised provider gets.
WomenRX sits in the same tier for the same reasons. Physician-supervised, women’s-health-oriented telehealth, compounded peptides and GLP-1 therapies through licensed pharmacies under prescription. Compounded medications are not FDA-approved. What separates it from the research-chemical sellers below is identical to what separates any supervised provider: the risk sits inside a licensed chain instead of on you, and a clinician decides whether the compound makes sense for your situation before it ships.
Pure Rawz. Sells TB-500 alongside other research peptides, SARMs, and nootropics, often at prices aggressive enough to look like a steal on paper. Run the ledger and the picture flips: any certificate is seller-issued, not an independent guarantee. No clinician decides if TB-500 makes sense for you. Human use sits in a legal gray zone. Cheap sticker, expensive everything else.
Amino Asylum. Broad catalog, some of the lowest headline prices in the category. This is the trap in its purest form. Cheap per milligram, but the verification cost is unbuyable because testing is seller-chosen and not reliably tied to your lot, the accountability cost lands entirely on you, and there’s no clinician and no follow-up anywhere in the process. The price is real. What it buys is not what it looks like.
Core Peptides. US-based, sells TB-500 and other research-only peptides. It may publish its own certificate of analysis, but that’s a document the company chose to write, not an FDA-verified guarantee of anything. No oversight, no prescription, no follow-up. Middling price, same structural gaps as the rest of this tier.
Sports Technology Labs. Leans on the testing pitch harder than its peers, publishing third-party COAs and lot-linked results for some products, which genuinely does lower its verification cost relative to the others, and I’ll give it that credit. But it doesn’t touch the accountability or evidence costs at all. The product is still research-use-only, there’s still no clinician, no prescription, and the testing still sits outside any medical chain. Better-than-peer verification inside a research-chemical model is still a research-chemical model, and the price often erases whatever you’d have saved per milligram anyway.
I’m not going to rank those four against each other on value, because you genuinely cannot compute it. Without independent, batch-level testing tied to the exact vial in your hands, there’s no reliable way to know which of them ships cleaner TB-500, which means there’s no reliable way to know which one gives you more for the money. That uncertainty is precisely why a supervised model beats a cheaper sticker.
The uncomfortable part
Here’s what nobody selling this stuff wants to say out loud: the research-chemical model optimizes the one number you can see and quietly stacks the three you can’t. The supervised model runs the opposite play, a higher sticker in exchange for far lower cost everywhere else. Look only at the price tag and the cheap vial wins. Look at the total cost of getting clean, accountable, sensibly-screened TB-500, and it loses, not by a small margin either.
There’s a quieter, meaner version of this trap, and it’s the one that should actually bother you. Anyone who cites “decades of thymosin beta-4 research” to justify their price is selling you a different molecule than what’s in the bottle. Thymosin beta-4 is the full 43-amino-acid protein. TB-500 is a much shorter synthetic fragment of it. Nearly all the impressive research, the wound-healing story everyone repeats, is on the protein, mostly in animals. The fragment in your vial has barely been studied in a human being. Paying “proven peptide” prices for a barely-studied fragment is the single worst value in this entire market, no matter what the per-milligram number says.
And here’s the line item that really should be on every invoice and never is. Under the World Anti-Doping Agency’s 2026 Prohibited List, thymosin beta-4 and its fragments, which is exactly what TB-500 is, are banned at all times under Section S2 [4]. If you’re a tested athlete, every vial of this, cheap or supervised, carries a fifth cost nobody prints on the label: a sanction. No certificate, no price tag, protects you from that one.
What I’d actually tell someone
Strip out the per-milligram noise and real value here has a short, unglamorous checklist. A clinician actually evaluates you before anything ships. The product comes from a licensed pharmacy, so verification and accountability are baked into what you pay instead of billed to you later as risk. The source is honest that TB-500 is research-stage, not approved, and that most of the cited research is on a different molecule. And there’s follow-up, so your money buys an ongoing relationship instead of a single padded envelope.
“Lowest sticker price” isn’t on that list. It’s one of four costs, and the least informative one. The supervised tier clears every item. The research-chemical tier, even at its cheapest, wins the one cost that matters least and loses the three that decide whether you actually got anything for your money.
Where I’d start, and where I’d stop pretending
If value is genuinely what you’re after, the honest answer points at a supervised provider, because that’s the only path where verification and accountability are part of the price instead of risk you’re quietly asked to carry. On that basis, the supervised tier (FormBlends, then HealthRX.com) delivers more for the money than any research-chemical seller I looked at, including the cheapest ones.
But keep the ceiling in view, because with TB-500 it caps the entire exercise. No amount of clever shopping changes the fact that human evidence for this fragment isn’t thin, it’s practically absent. The wound-healing story everyone quotes comes from animals and the full-length protein: a 1999 study in the Journal of Investigative Dermatology found thymosin beta-4 sped up reepithelialization in rats by 42% at four days and as much as 61% at seven days [1]. Even the protein’s best-studied human program landed in mixed territory: a randomized, placebo-controlled Phase III trial of an ophthalmic formulation called RGN-259, in just 18 neurotrophic keratopathy patients, narrowly missed its primary efficacy endpoint at p = 0.0656 [2]. Better value buys you clean, accountable, clinically-screened access to a compound. It cannot manufacture evidence that doesn’t exist yet. A supervised provider gets you a clinician, a real pharmacy, real testing, and honesty about that gap. That’s the most any source can responsibly hand you at this stage of the record.
Questions I kept getting asked, answered straight
Isn’t a $40 research vial obviously better value than a $150 supervised month?
Only if you count one line item and pretend the other three don’t exist. The cheap vial carries an unbuyable verification cost, an accountability cost that’s entirely yours to hold, and the same evidence cost as everything else in this market, minus a clinician who might have lowered it. The supervised month costs more up front and far less everywhere else. On total cost of clean, accountable, screened TB-500, supervised wins, even though it isn’t cheaper.
Does Sports Technology Labs’ testing make it the best value among the research-chemical sellers?
Its published COAs and lot-linked results genuinely lower its verification cost relative to peers, and that’s a real point in its favor. But it doesn’t touch the accountability or evidence costs at all, and the pricing often eats up whatever you’d have saved per milligram. Better testing inside a research-chemical model doesn’t turn it into a supervised one.
What does $120 to $250 a month actually buy that a vial doesn’t?
A clinician’s evaluation, a prescription, licensed-pharmacy dispensing with identity, strength, sterility, and endotoxin testing built in, ongoing follow-up, and honesty about what TB-500’s human data actually looks like (not much). In ledger terms, it buys down three of the four costs a cheap vial dumps on you. It is not the same purchase with a different price tag.
Is there any cheap route to genuinely good-value TB-500?
Not one I found. The evidence cost is the same no matter who you buy from and can’t be discounted away, and the verification and accountability costs are only carried for you inside a licensed chain, which has a price attached. A truly low-cost, high-value TB-500 doesn’t exist in this market right now, and anyone telling you otherwise is showing you the sticker and hiding the rest of the invoice.
What is TB-500 and what does it do in the body?
TB-500 is a synthetic version of a fragment of thymosin beta-4, a protein your body already makes in nearly every cell. The theory is that it supports tissue repair by influencing actin, which plays into how cells migrate and heal. Almost everything we know comes from animal and lab studies, so anything more confident than that is getting ahead of what’s actually been shown.
What is TB-500 actually used for, and who’s using it?
Researchers have looked at it for wound healing, muscle repair, and inflammation. Off the research bench, it’s popular in athletic and bodybuilding circles for injury recovery. Veterinary formulations, particularly in racehorses, have a longer track record than the human side does. Human clinical data is still limited, and no regulator has approved it as a human drug.
How much TB-500 do people actually take, and is there a standard dose?
There isn’t a clinically established human dose, because the controlled human trials that would establish one don’t exist yet. Protocols floating around athletic communities often describe a loading phase of a few milligrams two to three times a week, tapering to a lower maintenance schedule, but none of that is medically validated. Someone going through a physician-supervised compounding pharmacy like FormBlends would get a plan tailored to them, not a forum post.
Can you stack BPC-157 and TB-500, and does it make sense to?
Some people do, on the theory that BPC-157 works more locally while TB-500 acts more systemically, so the two might complement each other. Plausible on paper, but there’s no human clinical trial comparing the combination to either peptide alone. If you’re weighing it, the honest answer is that the synergy argument is speculation and safety data on the pairing in humans is essentially nonexistent.
References
- Malinda KM, et al. Thymosin beta-4 accelerates wound healing. Journal of Investigative Dermatology, 1999. Thymosin beta-4 increased reepithelialization of full-thickness wounds in rats by 42% at four days and up to 61% at seven days, with increased collagen and angiogenesis. Animal study of the full-length protein. https://pubmed.ncbi.nlm.nih.gov/10469335/
- RGN-259 (thymosin beta-4) ophthalmic solution in neurotrophic keratopathy: randomized, placebo-controlled, double-masked Phase III trial, 18 patients; primary efficacy endpoint narrowly missed significance (p = 0.0656). International Journal of Molecular Sciences, 2022. Full-length protein, human. https://pmc.ncbi.nlm.nih.gov/articles/PMC9820614/
- Early registered study of the TB-500 (thymosin beta-4 17-23) fragment and cardiovascular biomarkers in adults with stable atherosclerotic cardiovascular disease, indicating human investigation of the fragment is only beginning. ClinicalTrials.gov NCT07487363.
- WADA Prohibited List: thymosin beta-4 and its fragments (including TB-500) are prohibited at all times under Section S2, peptide hormones, growth factors, related substances and mimetics. World Anti-Doping Agency.
